“…As an alternative approach, Leist et al developed a mouse-adapted SARS-CoV-2 strain (namely, MA10) engineered to bind mACE2 and to which conventional mouse strains are permissive ( 34 ). To date, the vast majority of the studies in the literature have evaluated the pathogenicity of Wuhan-like SARS-CoV-2 and VOCs (i.e., Alpha, Beta, Delta, and Omicron variants) in K18-hACE2 mice ( 35 , 53 – 55 ), with only a single study evaluating the replication of the mouse-adapted MA10 strain in this specific mouse model ( 39 ). Thus, far, no in-depth characterization of the differences in infection dynamics and pathophysiology between the mouse-adapted MA10 strain and the counterpart USA-WA1/2020 in K18-hACE2 mice has been undertaken.…”